2023
Factors Affecting Antidepressant Response Trajectories: A Veterans Affairs Augmentation and Switching Treatments for Improving Depression Outcomes Trial Report
Hicks P, Sevilimedu V, Johnson G, Tal I, Chen P, Davis L, Vertrees J, Zisook S, Mohamed S. Factors Affecting Antidepressant Response Trajectories: A Veterans Affairs Augmentation and Switching Treatments for Improving Depression Outcomes Trial Report. Psychiatric Research And Clinical Practice 2023, 5: 131-143. PMID: 38077276, PMCID: PMC10698706, DOI: 10.1176/appi.prcp.20230017.Peer-Reviewed Original ResearchGroup-based trajectory modelingBaseline depressionEarly improvementSwitching treatmentSingle-blind trialHigher baseline depressionDepression symptom changeAdditional exploratory analysesAssociation of treatmentMajor depressive disorderLogistic regression analysisDepression Outcomes studyDemographic factorsMultinomial logistic regression analysisSpecific depression symptomsExploratory analysisProbability of responseAntidepressant trialsSeverity scoreDepressive disorderTrial reportsOutcome studiesBaseline anxietyPrimary analysisTreatment interventions
2022
Childhood adversity and adulthood major depressive disorder
Zisook S, Planeta B, Hicks PB, Chen P, Davis LL, Villarreal G, Sapra M, Johnson GR, Mohamed S. Childhood adversity and adulthood major depressive disorder. General Hospital Psychiatry 2022, 76: 36-44. PMID: 35366613, DOI: 10.1016/j.genhosppsych.2022.03.008.Peer-Reviewed Original ResearchConceptsMajor depressive disorderChildhood adversityDepressive disorderSuicidal ideationLower remission rateLower depression severityDepression Outcomes studyMore lifetime episodesGOV IDENTIFIERRemission rateClinical featuresClinical outcomesSevere depressionTreatment strategiesLifetime episodesOutcome studiesDepression severitySwitching treatmentYounger ageSecondary analysisComorbid PTSDChildhood maltreatmentWorse qualitySpecific typesDisorders
2019
Predictability of Nonremitting Depression After First 2 Weeks of Antidepressant Treatment: A VAST‐D Trial Report
Hicks P, Sevilimedu V, Johnson G, Tal I, Chen P, Davis L, Vertrees J, Mohamed S, Zisook S. Predictability of Nonremitting Depression After First 2 Weeks of Antidepressant Treatment: A VAST‐D Trial Report. Psychiatric Research And Clinical Practice 2019, 1: 58-67. PMID: 36101874, PMCID: PMC9176018, DOI: 10.1176/appi.prcp.20190003.Peer-Reviewed Original ResearchNegative predictive valuePositive predictive valueEarly improvementWeek 2Antidepressant therapyAntidepressant treatmentPredictive valueSingle-blind trialDepressive Symptomatology-Clinician RatedMajor depressive disorderDepression Outcomes studyWeek 12Medication interventionsQuick InventoryDepressive disorderWeek 6Trial reportsOutcome studiesTreatment groupsDegree of improvementSwitching treatmentClinical decisionSecondary analysisRemissionMinimal improvementGeneral Predictors and Moderators of Depression Remission: A VAST-D Report
Zisook S, Johnson GR, Tal I, Hicks P, Chen P, Davis L, Thase M, Zhao Y, Vertrees J, Mohamed S. General Predictors and Moderators of Depression Remission: A VAST-D Report. American Journal Of Psychiatry 2019, 176: 348-357. PMID: 30947531, DOI: 10.1176/appi.ajp.2018.18091079.Peer-Reviewed Original ResearchMeSH KeywordsAdultAdverse Childhood ExperiencesAgedAged, 80 and overAntidepressive AgentsAripiprazoleBupropionDepressive Disorder, MajorDrug SubstitutionDrug Therapy, CombinationEmploymentFemaleGriefHumansLife TablesMaleMiddle AgedPrognosisQuality of LifeRemission InductionSeverity of Illness IndexSingle-Blind MethodUnited StatesUnited States Department of Veterans AffairsYoung AdultConceptsNext-step treatmentsRelease bupropionVeterans Health Administration patientsPatients' baseline featuresSingle-blind trialMajor depressive disorderDepression Outcomes studyComplicated grief symptomsAntidepressant treatmentBaseline characteristicsInitial treatmentDepression remissionDepressive disorderRemissionOutcome studiesTreatment selectionTreatment groupsHypomanic symptomsSwitching treatmentClinical imperativePositive mental healthChildhood adversityPatientsMental healthSpecific augmentation
2015
The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations
Mohamed S, Johnson GR, Vertrees JE, Guarino PD, Weingart K, Young IT, Yoon J, Gleason TC, Kirkwood KA, Kilbourne AM, Gerrity M, Marder S, Biswas K, Hicks P, Davis LL, Chen P, Kelada A, Huang GD, Lawrence DD, LeGwin M, Zisook S. The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations. Psychiatry Research 2015, 229: 760-770. PMID: 26279130, DOI: 10.1016/j.psychres.2015.08.005.Peer-Reviewed Original Research